Market revenue in 2023 | USD 22.9 million |
Market revenue in 2030 | USD 31.6 million |
Growth rate | 4.7% (CAGR from 2023 to 2030) |
Largest segment | Phase iii |
Fastest growing segment | Phase I |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | Novartis AG ADR, Labcorp Holdings Inc, Medpace Holdings Inc, Charles River Laboratories International Inc, Icon PLC, GlaxoSmithKline Consumer Healthcare (GSK CH India), Aurora Innovation Inc Class A, Biogen Inc, IQVIA Holdings Inc, inVentiv Health |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to neurology clinical trials market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 41.05% in 2023. Horizon Databook has segmented the South Africa neurology clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
The South Africa neurology clinical trials market is expected to witness growth owing to presence of a well-established infrastructure, diverse population, availability of experts, formation of separate drug regulatory agency, and easy patient recruitment.
South Africa was once a commonly considered country for clinical research, but its popularity generated bottlenecks in the country's previously built regulatory structure. Biotechnology and pharmaceutical corporations began pressuring for reform and actively lobbied the South African government. Their efforts compelled the Minister of Health to take initiatives.
The South African government overhauled its whole regulatory environment, establishing SAHPRA to oversee clinical trial evaluation and approval as well as medicinal approvals. Such initiatives are likely to promote the market in South Africa.
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa neurology clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into South Africa neurology clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account